Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,041.3
-79.3 (-2.54%)

 

  • STI Straits Times Index
    3,041.3
    -79.3 (-2.54%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,514.0
    3.4 (0.23%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    23,475.3
    -377.0 (-1.58%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,563.9
    1.2 (0.03%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    27,821.8
    -462.2 (-1.63%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,533.9
    -74.4 (-1.13%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 2,947.1M
  • Value: 3,865.3M
  • Rise: 100
  • Fall: 254
  • Unch: 403

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Lippo Malls Tr0.054-
Singtel2.360-0.050
Sembcorp Marine0.085+0.002
Genting Sing0.770-0.020
Medtecs Intl0.440-0.060
HGH0.020+0.001
ComfortDelGro1.370-0.060
CapLand IntCom T2.110-0.030
Ascendas Reit2.920-0.070
ThaiBev0.670-0.015

World Indices

World Indices
Name Last Change
Nasdaq 15,782.8 +291.2
HSI 23,475.3 -377.0
HSCEI 8,368.5 -129.8
Jakarta 6,533.9 -74.4
Nikkei 225 27,821.8 -462.2
SSE Comp 3,563.9 +1.2
Shanghai A 3,735.2 +1.3
Shanghai B 279.4 -1.1
KOSPI 2,839.0 -70.3

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

ACURX PHARMACEUTICALS INC ACURX PHARMACEUTICALS LLC
Updated on 29 Nov 2021 (End of trading day)
Last (USD): 5.060 Change: +0.170 High: 5.500 Remarks: -
Change (%): +3.48 Low: 5.040

Company Background

Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. It focuses on developing new antibiotics for difficult to treat infections. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its research & development pipeline includes early stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin- Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.

Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.45029 Trailing EPS (USD) b -0.45029 NAV (USD) c 1.3976
PE a - Trailing PE d - Price / NAV c 3.6205
Dividend Yield (%) e - Cash In Hand (USD) f 1.4154 Issued & Paid-up Shares g 10,215,800
Piotroski F Score 3 Market Cap (M) 51.692 Free Float (%) 70.2
Return on Equity (ROE) (%) h n.m. Revenue Growth (%) TTM i n.m.
Net Earnings Growth (%) j 22.444 Net Debt/Equity k Net Cash
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted based on Profit Attributable To Shareholders.
  2. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  3. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  4. Based on latest Full Year results announcement, adjusted for the current number of shares.
  5. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  6. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  7. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 23 Nov 2021. Please click here for more information.
  8. Calculated based on Net Earnings / (Shareholders' Equity - Other Share Capital)
  9. Calculated based on (Current Year Revenue - Last Year Revenue) / Last Year Revenue
  10. Calculated based on (Current Year Earnings - Last Year Earnings) / Last Year Earnings
  11. Calculated based on (Long Term Debt + Short Term Debt - Cash and Short Term Investments)/(Shareholders' Equity - Other Share Capital)

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.400
+8.58 %
10 Days -+0.140
+2.85 %
20 Days --0.320
-5.95 %
Medium Term Return 3 Months --0.110
-2.13 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference ACURX PHARMACEUTICALS INC NASDAQ 51.692 - - 3.6205 -
Industry Pharmaceuticals: Major NASDAQ 2,155.854 85.491 91.614 2.7445 1.466
Local Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 172,048.044 53.832 116.960 4.3289 2.091
Local Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 121,829.080 8.679 17.592 1.6245 2.808
Local Peer ROYALTY PHARMA PLC NASDAQ 25,100.573 25.743 32.064 4.3329 0.464
Local Peer REPLIGEN CORP NASDAQ 16,098.905 268.646 135.423 9.3857 -
Local Peer VIATRIS INC NASDAQ 15,141.563 - - 0.7162 -
Local Peer EVOTEC SE SPON ADS EACH REP 0.50 ORD SHS NASDAQ 7,977.738 1,119.094 27.081 6.9344 -
Local Peer CUREVAC NV NASDAQ 8,721.178 - - - -
Local Peer ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS NASDAQ 8,030.562 - - 6.9741 -
Local Peer LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS NASDAQ 7,830.475 - - 34.6681 -
Local Peer HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS NASDAQ 5,883.379 - - 5.9743 -
Local Peer I MAB SPON ADS EACH REP 2.3 ORD SHS NASDAQ 4,959.931 72.698 72.698 5.7644 -
Local Peer CEREVEL THERAPEUTICS HLDGS INC NASDAQ 4,607.014 - - 7.3234 -
Other Local Peers ALLAKOS INC (NASDAQ), APELLIS PHARMACEUTICALS INC (NASDAQ), KARUNA THERAPEUTICS INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), OPKO HEALTH INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), ERASCA INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), ICOSAVAX INC (NASDAQ), GH RESEARCH PLC (NASDAQ), PROCAPS GROUP S.A. (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), GENERATION BIO CO (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), KRONOS BIO INC (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), 2SEVENTY BIO INC (NASDAQ), MINK THERAPEUTICS INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), PETIQ INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), VERU INC (NASDAQ), ESSA PHARMA INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), BEYONDSPRING INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), XILIO THERAPEUTICS INC (NASDAQ), ANNEXON INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), PHARVARIS NV (NASDAQ), PROVENTION BIO INC (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), PYXIS ONCOLOGY INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), AC IMMUNE SA (NASDAQ), TRICIDA INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), BROOKLYN IMMUNO THERAPEUTICS INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), EVOLUS INC (NASDAQ), COMPASS THERAPEUTICS INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), CLENE INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), HARROW HEALTH INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), 89BIO INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), XOMA CORP (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), VINCERX PHARMA INC (NASDAQ), DURECT CORP (NASDAQ), IMMUNIC INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), ATHENEX INC (NASDAQ), ALZAMEND NEURO INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), MUSTANG BIO INC (NASDAQ), OBSEVA SA (NASDAQ), INOZYME PHARMA INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), NEXIMMUNE INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), JOURNEY MEDICAL CORPORATION (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), POLYPID LTD (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), CLARUS THERAPEUTICS HLDGS INC (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), EYENOVIA INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), ENTERA BIO LTD (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), PROPHASE LABS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), NOVAN INC (NASDAQ), BIOFRONTERA INC (NASDAQ), ABVC BIOPHARMA INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), IMARA INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), GENPREX INC (NASDAQ), GALECTO INC (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), MANNATECH INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), MEDIWOUND LTD (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), SYNAPTOGENIX INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), GRAYBUG VISION INC (NASDAQ), RENOVORX INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), PASITHEA THERAPEUTICS CORP (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), VIRPAX PHARMA INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ),